214 related articles for article (PubMed ID: 37474833)
1. Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy.
Coorens THH; Collord G; Treger TD; Adams S; Mitchell E; Newman B; Getz G; Godfrey AL; Bartram J; Behjati S
Nat Cancer; 2023 Aug; 4(8):1095-1101. PubMed ID: 37474833
[TBL] [Abstract][Full Text] [Related]
2. Lineage Switch in an Infant B-Lymphoblastic Leukemia With t(1;11)(p32;q23);
Du J; Chisholm KM; Tsuchiya K; Leger K; Lee BM; Rutledge JC; Paschal CR; Summers C; Xu M
Pediatr Dev Pathol; 2021; 24(4):378-382. PubMed ID: 33749383
[TBL] [Abstract][Full Text] [Related]
3. Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy.
Rayes A; McMasters RL; O'Brien MM
Pediatr Blood Cancer; 2016 Jun; 63(6):1113-5. PubMed ID: 26914337
[TBL] [Abstract][Full Text] [Related]
4. Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy.
Semchenkova A; Mikhailova E; Komkov A; Gaskova M; Abasov R; Matveev E; Kazanov M; Mamedov I; Shmitko A; Belova V; Miroshnichenkova A; Illarionova O; Olshanskaya Y; Tsaur G; Verzhbitskaya T; Ponomareva N; Bronin G; Kondratchik K; Fechina L; Diakonova Y; Vavilova L; Myakova N; Novichkova G; Maschan A; Maschan M; Zerkalenkova E; Popov A
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409391
[TBL] [Abstract][Full Text] [Related]
5. Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against
Niswander LM; Graff ZT; Chien CD; Chukinas JA; Meadows CA; Leach LC; Loftus JP; Kohler ME; Tasian SK; Fry TJ
Haematologica; 2023 Feb; 108(2):457-471. PubMed ID: 35950535
[TBL] [Abstract][Full Text] [Related]
6. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A
Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435
[TBL] [Abstract][Full Text] [Related]
7. Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement.
Zoghbi A; Zur Stadt U; Winkler B; Müller I; Escherich G
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28453885
[TBL] [Abstract][Full Text] [Related]
8. Therapy-induced Deletion in 11q23 Leading to Fusion of
Panagopoulos I; Andersen K; Eilert-Olsen M; Zeller B; Munthe-Kaas MC; Buechner J; Osnes LTN; Micci F; Heim S
Cancer Genomics Proteomics; 2021; 18(1):67-81. PubMed ID: 33419897
[TBL] [Abstract][Full Text] [Related]
9. Reasons for optimism in the therapy of acute leukemia.
Rowe JM
Best Pract Res Clin Haematol; 2015; 28(2-3):69-72. PubMed ID: 26590761
[TBL] [Abstract][Full Text] [Related]
10. Extramedullary relapse of
Aldoss I; Song JY
Blood; 2018 May; 131(22):2507. PubMed ID: 29853461
[No Abstract] [Full Text] [Related]
11. Targeting FLT3-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia with KMT2A rearrangement.
Suematsu M; Yagyu S; Yoshida H; Osone S; Nakazawa Y; Sugita K; Imamura T; Iehara T
Cancer Immunol Immunother; 2023 Apr; 72(4):957-968. PubMed ID: 36214866
[TBL] [Abstract][Full Text] [Related]
12. Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia.
Wullenkord R; Reicherts C; Mikesch JH; Marx J; Wethmar K; Albring J; Call S; Lenz G; Stelljes M
Ann Hematol; 2021 Feb; 100(2):587-589. PubMed ID: 32829460
[No Abstract] [Full Text] [Related]
13. Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia.
Oberley MJ; Gaynon PS; Bhojwani D; Pulsipher MA; Gardner RA; Hiemenz MC; Ji J; Han J; O'Gorman MRG; Wayne AS; Raca G
Pediatr Blood Cancer; 2018 Sep; 65(9):e27265. PubMed ID: 29797659
[TBL] [Abstract][Full Text] [Related]
14. Lineage switch of KMT2A-rearranged adult B-lineage acute lymphoblastic leukemia following bispecific T-cell engager and monoclonal antibody therapy.
Wu JR; Shih PC; Li C; Chao HL; Wang HC; Chiang YM; Liu YJ; Hsu SC; Yao CY; Chen LH; Lin CC; Tien HF; Chou WC
J Hematop; 2023 Jun; 16(2):103-109. PubMed ID: 38175441
[TBL] [Abstract][Full Text] [Related]
15. Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib.
El Chaer F; Holtzman NG; Sausville EA; Law JY; Lee ST; Duong VH; Baer MR; Koka R; Singh ZN; Hardy NM; Emadi A
Acta Haematol; 2019; 141(2):107-110. PubMed ID: 30695783
[TBL] [Abstract][Full Text] [Related]
16. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR
Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832
[TBL] [Abstract][Full Text] [Related]
17. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
Le Jeune C; Thomas X
Drug Des Devel Ther; 2016; 10():757-65. PubMed ID: 26937176
[TBL] [Abstract][Full Text] [Related]
18. CD19 expression in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia pre- and post-treatment with blinatumomab.
Mejstrikova E; Klinger M; Markovic A; Zugmaier G; Locatelli F
Pediatr Blood Cancer; 2021 Dec; 68(12):e29323. PubMed ID: 34519430
[TBL] [Abstract][Full Text] [Related]
19. Blinatumomab for the treatment of acute lymphoblastic leukemia.
Kaplan JB; Grischenko M; Giles FJ
Invest New Drugs; 2015 Dec; 33(6):1271-9. PubMed ID: 26383529
[TBL] [Abstract][Full Text] [Related]
20. Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab.
Sutton R; Pozza LD; Khaw SL; Fraser C; Revesz T; Chamberlain J; Mitchell R; Trahair TN; Bateman CM; Venn NC; Law T; Ong E; Heatley SL; McClure BJ; Meyer C; Marschalek R; Henderson MJ; Cross S; White DL; Kotecha RS
Pediatr Blood Cancer; 2021 May; 68(5):e28922. PubMed ID: 33638292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]